Gilteritinib Fumarate Patent Expiration

Gilteritinib Fumarate is Used for treating acute myeloid leukemia. It was first introduced by Astellas Pharma Us Inc in its drug Xospata on Nov 28, 2018.


Gilteritinib Fumarate Patents

Given below is the list of patents protecting Gilteritinib Fumarate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xospata US10786500 Stable pharmaceutical composition for oral administration Jul 01, 2036 Astellas
Xospata US11938130 Stable pharmaceutical composition for oral administration Jul 01, 2036 Astellas
Xospata US11938131 Stable pharmaceutical composition for oral administration Jul 01, 2036 Astellas
Xospata US11938132 Stable pharmaceutical composition for oral administration Jul 01, 2036 Astellas
Xospata US11938133 Stable pharmaceutical composition for oral administration Jul 01, 2036 Astellas
Xospata US11944620 Stable pharmaceutical composition for oral administration Jul 01, 2036 Astellas
Xospata US8969336 Diamino heterocyclic carboxamide compound Nov 28, 2032 Astellas
Xospata US9487491 Diamino heterocyclic carboxamide compound Jul 28, 2030 Astellas


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Gilteritinib Fumarate's patents.

Given below is the list recent legal activities going on the following patents of Gilteritinib Fumarate.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 24 Apr, 2024 US9487491
Patent Issue Date Used in PTA Calculation 02 Apr, 2024 US11944620
Patent eGrant Notification 02 Apr, 2024 US11944620
Recordation of Patent eGrant 02 Apr, 2024 US11944620
Recordation of Patent Grant Mailed 02 Apr, 2024 US11944620
Mail Patent eGrant Notification 02 Apr, 2024 US11944620
Email Notification 02 Apr, 2024 US11944620
Payment of Maintenance Fee, 4th Year, Large Entity 29 Mar, 2024 US10786500
Patent Issue Date Used in PTA Calculation 26 Mar, 2024 US11938130
Email Notification 26 Mar, 2024 US11938130



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳